Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001628280-26-034079
Filing Date
2026-05-12
Accepted
2026-05-12 16:02:23
Documents
3
Period of Report
2026-05-08

Document Format Files

Seq Description Document Type Size
1 FORM 3 wk-form3_1778616140.html 3  
1 FORM 3 wk-form3_1778616140.xml 3 4301
2 EX-24 schelmanwilliam-powerofa.htm EX-24 5025
3 schelmanwilliam-powerofa001.jpg GRAPHIC 284587
  Complete submission text file 0001628280-26-034079.txt   402813
Mailing Address 116 HUNTINGTON AVENUE SUITE 703 BOSTON MA 02116
Business Address 116 HUNTINGTON AVENUE SUITE 703 BOSTON MA 02116 617-468-4219
Bicara Therapeutics Inc. (Issuer) CIK: 0002023658 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address BICARA THERAPEUTICS INC. 116 HUNTINGTON AVE, SUITE 703 BOSTON MA 02116
Business Address
Schelman William (Reporting) CIK: 0002132269 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-42271 | Film No.: 26968324